Yuki Nakamura_No.4

Q: How did the anthor address the question?

■Step1 1. Identification of cMAF as a transcription factor that regulates PVM Using single-cell multi-omics, they analyzed the transcriptional and regulatory programs of brain macrophages and identified cMAF as the primary transcription factor characterizing PVM. They demonstrated that conditional deletion of cMAF disrupts the normal phenotype of PVM, indicating that cMAF is essential for maintaining PVM identity. They established that cMAF is a central transcriptional regulator defining PVM. ■Step2 2. Elucidation of the functional axis: cMAF → IGF-1 → endothelial cells They discovered that cMAF regulates the expression of IGF-1 (insulin-like growth factor 1) in the PVM and demonstrated that PVM-derived IGF-1 mediates communication with endothelial cells. When cMAF was depleted in the PVM, transcriptional alterations occurred not only in the PVM itself but also in the cerebral arteries, affecting vascular function. In other words, they demonstrated that cMAF in the PVM induces IGF1 expression and maintains cerebral vascular function through PVM–endothelial cell communication. ■Step3 3. Demonstrating that the cMAF-dependent program is conserved in humans, with implications for Alzheimer's disease and APOE4 Analysis of human PVM also identified cMAF as a major transcription factor. In Alzheimer’s disease, a response occurs in which increased cMAF in the PVM leads to increased IGF1, which in turn enhances communication with vascular cells; this response may have a protective effect against Alzheimer’s disease. Furthermore, they demonstrated that this cMAF–IGF1 response is abrogated in APOE4 carriers, who are at genetic risk for Alzheimer’s disease. In other words, they found that the cMAF–IGF1 axis in the PVM is conserved in humans and is involved in an adaptive and protective vascular response against Alzheimer’s disease, but that this response is impaired in APOE4 carriers.

kawaokashinpei3

9月24日

読了時間: 2分

Selected journal : Cell

Brain perivascular macrophages regulate endothelial cell function via a cMAF-dependent transcriptional program in mouse and human

https://doi.org/10.1016/j.cell.2026.07.043

What is the main question of the paper?

What transcriptional programs do perivascular macrophages (PVMs) use to maintain their cellular state and function and to regulate cerebral endothelial cells?

How did the anthor address the question?

■Step1

1. Identification of cMAF as a transcription factor that regulates PVM

Using single-cell multi-omics, they analyzed the transcriptional and regulatory programs of brain macrophages and identified cMAF as the primary transcription factor characterizing PVM. They demonstrated that conditional deletion of cMAF disrupts the normal phenotype of PVM, indicating that cMAF is essential for maintaining PVM identity. They established that cMAF is a central transcriptional regulator defining PVM.

■Step2

2. Elucidation of the functional axis: cMAF → IGF-1 → endothelial cells

They discovered that cMAF regulates the expression of IGF-1 (insulin-like growth factor 1) in the PVM and demonstrated that PVM-derived IGF-1 mediates communication with endothelial cells. When cMAF was depleted in the PVM, transcriptional alterations occurred not only in the PVM itself but also in the cerebral arteries, affecting vascular function. In other words, they demonstrated that cMAF in the PVM induces IGF1 expression and maintains cerebral vascular function through PVM–endothelial cell communication.

■Step3

3. Demonstrating that the cMAF-dependent program is conserved in humans, with implications for Alzheimer's disease and APOE4

Analysis of human PVM also identified cMAF as a major transcription factor. In Alzheimer’s disease, a response occurs in which increased cMAF in the PVM leads to increased IGF1, which in turn enhances communication with vascular cells; this response may have a protective effect against Alzheimer’s disease. Furthermore, they demonstrated that this cMAF–IGF1 response is abrogated in APOE4 carriers, who are at genetic risk for Alzheimer’s disease. In other words, they found that the cMAF–IGF1 axis in the PVM is conserved in humans and is involved in an adaptive and protective vascular response against Alzheimer’s disease, but that this response is impaired in APOE4 carriers.

What is the “strength” of the paper?

The strength of this study lies in the fact that it has established the molecular-level identity and physiological function of the PVM, a cell population that was previously known but whose function was unclear. Furthermore, the study presents a clear line of reasoning, ranging from the demonstration of causality using conditional knockout to the effects on adjacent vascular endothelial cells and the link to human diseases and genetics.

Comment

I found a very interesting point in this paper. The researchers discovered a specific protective genetic mutation (rs450674) in humans. People who carry this mutation naturally produce more IGF-1 in their PVMs. This significantly lowers their risk of developing Alzheimer's disease. This finding is very important because it provides a clear target for future drug development. If a new drug can mimic the effects of this mutation, it might help protect the brain from the disease.

Comment by Xiaoran Ma